Destroying senescent cells in the aging stem cell niche, either genetically or pharmacologically using the small-molecule senolytic ABT-263 (navitoclax; Abbvie Inc.), enhanced hippocampal neurogenesis and cognitive function in mice, a Canadian study led by scientists at the University of Toronto has found.

Researchers at the Center for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh reported in the May 19, 2021, issue of Science Translational Medicine that the Bcl2/w/xL targeting senolytic compound, ABT-263 (navitoclax) could reverse the age-related fibrosis characteristic of and improve kidney function.